UBS Group Analysts Give Bayer (FRA:BAYN) a €110.00 Price Target

UBS Group set a €110.00 ($127.91) price target on Bayer (FRA:BAYN) in a research report released on Tuesday, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

Other equities research analysts have also issued research reports about the company. DZ Bank raised Telefonica from a hold rating to a buy rating in a report on Tuesday, May 14th. Goldman Sachs Group reaffirmed a buy rating and issued a $70.00 price objective on shares of Total in a report on Monday. HSBC set a €63.00 ($73.26) price objective on Bayer and gave the company a neutral rating in a report on Monday, July 1st. Baader Bank set a €123.00 ($143.02) price objective on Bayer and gave the company a buy rating in a report on Thursday, June 27th. Finally, Kepler Capital Markets set a €70.00 ($81.40) price objective on Bayer and gave the company a neutral rating in a report on Thursday, June 27th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have given a buy rating to the company’s stock. Bayer presently has a consensus rating of Hold and a consensus target price of €80.67 ($93.81).

Shares of BAYN opened at €59.96 ($69.72) on Tuesday. Bayer has a twelve month low of €91.58 ($106.49) and a twelve month high of €123.82 ($143.98). The firm has a 50 day simple moving average of €56.55.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: How Does the Quiet Period Work?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.